Skip to main navigation
FibroGen China
Newsroom
Contact
About Us
Our Company
Our Strategy
FibroGen China
Executive Team
Board of Directors
Scientific Advisory Board
Our Partners
ESG
Medical Information
Contact Us
Focus Areas
Our Expertise
Pancreatic Cancer
Prostate Cancer
Duchenne Muscular Dystrophy
Anemia
Publications
Pipeline
R&D Pipeline
Pamrevlumab
Roxadustat
FG-3246
Clinical Trials
Our Priorities
Pamrevlumab Trials
FG-3246 Trials
Careers
Our Culture
Career Opportunities
Investors and Media
Investor Relations
Investor Overview
Stock Information
News Releases
Events and Presentations
Corporate Governance
SEC Filings
Financial Information
Shareholder Services
Investor FAQs
MENU
MENU
close x
About Us
Our Company
Our Strategy
FibroGen China
Executive Team
Board of Directors
Our Partners
ESG
Medical Information
Contact Us
Focus Areas
Our Expertise
Pancreatic Cancer
Prostate Cancer
Duchenne Muscular Dystrophy
Anemia
Publications
Pipeline
R&D Pipeline
Pamrevlumab
Roxadustat
FG-3246
Clinical Trials
Our Priorities
Roxadustat Trials
Pamrevlumab Trials
FG-3246 Trials
Careers
Our Culture
Career Opportunities
Investors and Media
Iphone menu
Investor Overview
Stock Information
Stock Quote
Stock Chart
Historical Price Lookup
Analyst Coverage
Press Releases
Events & Presentations
Corporate Governance
Documents & Charters
Committee Composition
Contact the Board
SEC Filings
Financial Information
Form 8937
Shareholder Services
Contact Investor Relations
E-mail Alerts
Investor FAQs
FibroGen China
Newsroom
Contact
Search
Investors and Media
Matthew Keller, Ph.D.
H.C. Wainwright
Investors and Media
Investor Overview
Stock Information
Press Releases
Events & Presentations
Corporate Governance
SEC Filings
Financial Information
Shareholder Services
Investor FAQs
FibroGen Inc.
Volume:
Minimum 15 minutes delayed. Source: LSEG
Investor and Media Contact
Investors:
David DeLucia, CFA
Chief Financial Officer
[email protected]
Shareholder Tools
Print Page
RSS Feeds
E-mail Alerts
